Acetylsalicylic acid as a potential regulator of prolidase-convertible pro-drugs in control and neoplastic cells

Farmaco

Volumn 59, Issue 9, 2004, Pages 679-684

  Chrzanowski, Krzysztof ^a   Bielawska, Anna ^a   Bielawski, Krzysztof ^a   Pałka, Jerzy ^a   Wołczyński, Sławomir ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acetylsalicylic acid; Breast cancer cells; Fibroblast; Pro drug; Prolidase; Proline analogue of melphalan

Indexed keywords

ACETYLSALICYLIC ACID; ENZYME INHIBITOR; MELPHALAN; PRODRUG; PROLINE DIPEPTIDASE; TRITIUM;

ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; CELL MEMBRANE; CELL TYPE; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFECT; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MEASUREMENT; STATISTICAL SIGNIFICANCE; THIN LAYER CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS; ASPIRIN; CELL LINE, TUMOR; CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; DIPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; PRODRUGS;

EID: 4344597151     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2004.04.008     Document Type: Article

References (23)

1. Farmer P.B. Metabolism and reactions of alkylating agents. Pharmacol. Therap. 35:1987;301-358
2. Calabresi P., Parks R.E. Jr. Goodman L.S., Gilman A. The Pharmacological Basis of Therapeutics. 1980;Mc Millan Publ. Co., Inc., New York
3. Connors T.A. Pinedo H.M., Chabner B. Cancer Chemotherapy Annual 6. 1984;Elsevier Sci. Publ. B.V, Amsterdam, New York, Oxford
4. Takakura Y., Takagi A., Hashida M., Sezeki H. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4:1987;293-300
5. Takahara Y., Atsumi R., Hashida M., Sezeki H. Development of a novel polymeric prodrug of mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration. Int. J. Pharm. 7:1987;145-152
6. Bai J.P.-F., Hu M., Subramanian P., Mosberg H.I., Amidon G.L. Utilization of peptide carrier system to improve intestinal absorption: targeting prolidase as a prodrug-converting enzyme. J. Pharm. Sci. 2:1992;113-116
7. Bielawska A., Bielawski K., Palka J. Prolidase as a prodrug converting enzyme. III. Synthesis of proline analogue of melphalan and their susceptibility to the action of prolidase. Ann. Acad. Med. Bialostoc. 44:1999;190-199
8. Chrzanowski K., Bielawska A., Bielawski K., Wolczyński S., Palka J. Cytotoxicity and effect on collagen biosynthesis of proline analogue of melphalan as a prolidase-convertible prodrug in cultured human skin fibroblasts. Il Farmaco. 56:2001;701-706
9. Chrzanowski K., Palka J. Proline analogue of melphalan as a prolidase-convertible pro-drug in breast cancer MCF-7 cells. Folia Hist. Et Cyto. 39:(Suppl. 2):2001;209-211
10. Chrzanowski K., Bielawska A., Palka J. Proline analogue of melphalan as a prodrug susceptible to the action of prolidase in breast cancer MDA-MB 231 cells. Il Farmaco. 58:2003;1113-1119
11. Endo F., Tanoue A., Nakai H., Hata A., Indo Y., Titani K., et al. Primary structure and gene localization of human prolidase. J. Biol. Chem. 264:1989;4476-4481
12. Phang J., Scriver C. Disorders of proline and hydroxyproline metabolism. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic Basis of Inherited Disease. 1989;577-597 McGraw Hill, New York
13. Jackson S., Dennis A., Greenberg M. Iminopeptiduria. A genetic defect in recycling collagen: a method for determining prolidase in red blood cells. Can. Med. Assoc. J. 113:1975;759-763
14. Chamson A., Voigtlander V., Myara I., Frey J. Collagen biosynthetic anomalies in prolidase deficiency: effect of glycyl-L-proline on the degradation of newly synthesized collagen. Clin. Physiol. Biochem. 7:1989;128-136
15. Karna E., Palka J., Chyczewski L., Slodkowska J., Bogdan J. Prolidase and prolinase activities in moderately and poorly differentiated lung adenocarcinoma. Ann. Acad. Med. Bialostoc. 42:1997;230-240
16. 1 integrin expression in moderately and poorly differentiated lung adenocarcinomas. Ann. Acad. Med. Bialostoc. 42:1997;241-250
17. Miltyk W., Karna E., Palka J. Inhibition of prolidase activity by non-steroid antiinflammatory drugs in cultured human skin fibroblasts. Pol. J. Pharmacol. 48:1996;609-613
18. Myara I., Charpentier C., Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: application to imidodipeptiduria. Clin. Chim. Acta. 125:1982;193-205
19. Chinard F.P. Photometric estimation of proline and ornithine. J. Biol. Chem. 199:1952;91-95
20. Lowry I., Rosenbergh N., Farr A., Randall I. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275
21. J. Carmichael, W. Degraff, A. Gazdar, J. Minna, J. Mitchell, Evaluation of a tetrazolinum-based semiautomated colorimetric assay: assessment of chemosensitivity testing, Cancer Res. 47 (1978) 936-942
22. Hill B.T. Studies on the transport and cellular distribution of chlorambucil in the Yoshida ascites sarcoma. Biochem. Pharmacol. 21:1972;495-502
23. Begleiter A., Goldenberg G.J. Uptake and decomposition of chlorambucil by L5178Y lymphoblasts in vitro. Biochem. Pharmacol. 32:1983;535-539